Promising Expectations for Pneumococcal Vaccination during COVID-19

Hyobin Im 1,†, Jinhui Ser 2,†, Uk Sim 2,3,* and Hoonsung Cho 2,*

1 Marketing Department, Pfizer Pharmaceuticals Korea, Pfizer Tower 110, Seoul 04631, Korea; hyo-bin.im@pfizer.com
2 Department of School of Materials Science & Engineering, Chonnam National University, Yongbong-ro 77, Gwangju 61186, Korea; jh_ser@jnu.ac.kr
3 Research Institute, NEEL Science, Incorporation, Yongbong-ro 77, Gwangju 61186, Korea
* Correspondence: usim@jnu.ac.kr (U.S.); cho.hoonsung@jnu.ac.kr (H.C.);
Tel.: +82-62-530-1718 (U.S.); +82-62-530-1717 (H.C.)
† These authors contributed equally to this manuscript.

Abstract: The emergence of new viral infections has increased over the decades. The novel virus is one such pathogen liable for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, popularly known as coronavirus disease 2019 (COVID-19). Most fatalities during the past century’s influenza pandemics have cooperated with bacterial co/secondary infections. Unfortunately, many reports have claimed that bacterial co-infection is also predominant in COVID-19 patients (COVID-19 associated co/secondary infection prevalence is up to 45.0%). In the COVID-19 pandemic, Streptococcus pneumoniae is the most common coinfecting pathogen. Half of the COVID-19 mortality cases showed co-infection, and pneumonia-related COVID-19 mortality in patients >65 years was 23%. The weakening of immune function caused by COVID-19 remains a high-risk factor for pneumococcal disease. Pneumococcal disease and COVID-19 also have similar risk factors. For example, underlying medical conditions on COVID-19 and pneumococcal diseases increase the risk for severe illness at any age; COVID-19 is now considered a primary risk factor for pneumococcal pneumonia and invasive pneumococcal disease. Thus, pneumococcal vaccination during the COVID-19 pandemic has become more critical than ever. This review presents positive studies of pneumococcal vaccination in patients with COVID-19 and other medical conditions and the correlational effects of pneumococcal disease with COVID-19 to prevent morbidity and mortality from co/secondary infections and superinfections. It also reports the importance and role of pneumococcal vaccination during the current COVID-19 pandemic era to strengthen the global health system.

Keywords: COVID-19; SARS-CoV-2; Streptococcus pneumoniae; co/secondary infections; superinfections; pneumococcal vaccination

1. Overview of COVID-19
1.1. COVID-19 Outbreak

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in December 2019, and the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a global pandemic on 11 March 2020 [1]. As of 15 December 2021, over 270.7 million cases have been reported globally, with more than 5 million deaths in 192 countries and territories [2].

To date, the COVID-19 pandemic remains a demanding public health challenge. The disease itself is an acute respiratory illness that causes a higher mortality rate in people older than 60 years and in those with underlying medical conditions, including cardiovascular disease, chronic respiratory disease, diabetes, and cancer.
1.2. COVID-19 Threat Factors

It has been established that many infectious diseases can cause severe medical conditions and deterioration in the quality of life among the elderly and those with comorbidities [3]. Therefore, advanced age and comorbidities are risk factors for more severe disease, increased probability of infection, and poor clinical outcomes [4]. In addition to its potential as a leading cause of death, COVID-19 can induce a worsened prognosis of underlying medical conditions that may increase mortality risk. In addition, certain medical conditions have been found to place people into a high-risk category for causing severe COVID-19 outcomes, including lung disease, cardiovascular disease, diabetes, and cancer [5–7]. Studies have even revealed that COVID-19 patients with comorbidities such as cardiovascular disease and cancer could be at a significantly increased risk of experiencing more severe outcomes [8–10]. Furthermore, such patients with a substantially higher risk of contracting a more severe illness were reported to be at a higher risk of dying from the disease, requiring intensive care unit (ICU) admission or ventilation in their disease management [11].

2. Overview of Streptococcus pneumoniae

*Streptococcus pneumoniae* (*S. pneumoniae*) is the most commonly reported bacteria associated with co/secondary infections [12]. It was the predominant coinciding pathogen during the influenza pandemics of the late 1800s [13] and has also been observed in the coinfection cases during the COVID-19 pandemic [14–16].

*S. pneumoniae* settles down in the upper respiratory tract of up to 30% of healthy adults and remains the primary global cause of community-acquired pneumonia (CAP) [16]. CAP continues to be a common cause of morbidity and mortality in adults, becoming one of the capital public health problems because of its medical and economic burden [17,18]. Studies have even reported that death was most likely in nearly 1 of 3 adults after 1 year of hospitalization due to CAP [19]. Consequently, the pneumococcal disease caused by *S. pneumoniae* has now been defined as a significant vaccine-preventable disease (VPD) [20]. Even now, the current public health impact of *S. pneumoniae* infection has been reduced by vaccine policies, with the administration of pneumococcal conjugate and polysaccharide vaccines for children and adults, respectively, as practiced in the United Kingdom (UK) [13].

Notably, the *S. pneumoniae* carriage rate in patients with SARS-CoV-2 has been reported to be higher than in noninfected patients; this could be pathogenic due to the weakened immune system of COVID-19 patients [15]. As such, administering pneumococcal 13-valent conjugate vaccine (PCV13) and pneumococcal 23-valent polysaccharide vaccine (PPSV23) would effectively prevent the most severe coinfections during the COVID-19 pandemic [12].

Given these findings, association with vaccinations that prevent lower respiratory tract infections may be changing the aspects of the COVID-19 pandemic. For example, the influenza vaccine has been administered to high-risk groups in combination with the pneumococcal vaccine [21]. Therefore, pneumococcal vaccination has become an even more critical preventive measure, especially during the COVID-19 pandemic [15].

3. Overlapping Risk Factors for Infection by Two Respiratory Pathogens

COVID-19 may infect anybody and produce symptoms ranging from moderate (fever, cough) to severe (difficulty breathing, persistent discomfort, or pressure in the chest), similar to those associated with other respiratory viruses [22]. Both pneumococcal disease and COVID-19 have similar risk factors, such as old age, cancer, diabetes mellitus, asthma, smoking, and chronic heart, kidney, and liver illnesses (Table 1). The U.S. Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) [23], and a UK cohort study [1], described specific groups at risk among adults infected with COVID-19. These groups had underlying medical conditions, including old age, cancer, heart conditions (such as heart failure, coronary artery disease, cardiomyopathies), chronic vascular disease, hypertension, chronic kidney disease, chronic lung disease, diabetes,
asthma, smoking, pregnancy, and human immunodeficiency virus (HIV) infection [24,25]. The WHO has stated that the most common diagnosis for COVID-19 is severe pneumonia due to acute respiratory infection [26]. The CDC has further mentioned that the risk factors for pneumococcal pneumonia are old age, cancer, chronic heart disease, chronic kidney disease, chronic lung disease, diabetes, smoking, no spleen, HIV infection, nephrotic syndrome, cochlear implants, cerebrospinal fluid leaks, and chronic alcoholism [27].

Table 1. Correlation between the COVID-19 and pneumococcal disease risk groups.

| Disease               | COVID-19 | Pneumococcal | Research Articles |
|-----------------------|----------|---------------|-------------------|
| Ref Risk Factor       | CDC [28] | UK [1]        | Australia [29]    | CDC [30] | CANADA [31] | |
| Lung Disease          | 1        | 1             | 1                 | 1        | 1           | 12 [19,28,30,32–40] |
| Heart Disease         | 1        | 1             | 1                 | 1        | 1           | 11 [28,30,32–38,40] |
| Kidney Disease        | 1        | 1             | 1                 | 1        | 1           | 8 [28,30,33,34,36–39] |
| Liver Disease         | 1        | 1             | 1                 | 1        | 1           | 9 [28,30,32–35,37–39] |
| Diabetes              | 1        | 1             | 1                 | 1        | 1           | 12 [19,28,30,32–40] |
| Cancer                | 1        | 1             | 1                 | 1        | 1           | 5 [32–44,37,38] |
| Neurologic disorders  | 1        | 1             | 1                 | 1        | 1           | 1 [40] |
| Sickle cell disease   | 1        | 1             | 1                 | 1        | 1           | 2 [37,38] |
| HIV infection         | 1        | 1             | 1                 | 1        | 1           | 8 [28,30,32,33,36–39] |
| Stroke                | 1        | 1             | 1                 | 1        | 1           | 4 [19,30,36,37] |
| Rheumatoid arthritis  | 1        | 1             | 1                 | 1        | 1           | 1 [37] |
| Smoking               | 1        | 1             | 1                 | 1        | 1           | 6 [19,28,30,35,36,40] |

In this review, we observed that the risk factors for COVID-19 and pneumococcal pneumonia were relatively similar and focused on risk factors that significantly impacted COVID-19. We detail recommendations for pneumococcal vaccination from the CDC, WHO, and public health institutes of various countries. Among the COVID-19 and pneumococcal disease risk groups, patients with lung disease and diabetes need the utmost attention since these are two the most relevant diseases, as mentioned in all government guidelines and research papers shown in (Table 1). The risk groups have been mentioned in many research papers in the United States [19,32], France [33], Germany [28], Japan [34], South Korea [35], Spain [30,36], UK [37,38], and in Harrison’s 20th book [39]. Heart, liver, and kidney disease, HIV infection, cancer, smoking, stroke, sickle cell disease, and neurologic disorders are the following most relevant factors in that specific order. The UK, Australia, and the CDC have consistently mentioned that patients with cancer and heart, kidney, and liver diseases are more prone to contract COVID-19. However, risk factors such as rheumatoid arthritis showed the least propensity to lead to COVID-19 and pneumococcal disease.

Since the relationship between COVID-19 and pneumococcal risk groups is consistent, we believe that it would be prudent to consider the COVID-19 risk group as an addition to the pneumococcal vaccination guidelines in the future.

3.1. Age

Susceptibility to pneumococcal infections varies with age; infants and older adults are the most susceptible [41]. A cohort study from Louisville, KY, USA reported that the annual incidence of adult patients hospitalized with CAP was 634 (95% CI, 613.6–654.4) per 100,000. The incidence among the elderly from 2007 to 2009 was 1208 for patients aged 65–74 years, 2398 for those aged 75–84 years, and 4396 for patients ≥ 85 years of age [19]. Similarly, old age is a major risk factor for severe COVID-19 outcomes. According to the CDC, people over 65 years accounted for more than 80% of COVID-19 mortalities [24]. Moreover, according to Public Health England, the COVID-19 mortality rate was found to be 70 times greater among patients aged ≥ 80 years than in those aged < 40 years [42].
Hence, the WHO and the CDC recommend annual influenza vaccination and pneumococcal conjugate vaccinations for all employees and staff, following their local policies. As these infections are a significant cause of respiratory death in patients aged ≥ 65 years, vaccinations in this population need to be taken seriously [43,44].

3.2. Chronic Obstructive Pulmonary Disease (COPD)

COPD is a developing lung condition characterized by an accelerated reduction in lung function with disease exacerbations [45]. Concerning pneumonia, COPD is one of its most frequent comorbid conditions and is a crucial risk factor for its development. COPD comorbidity analysis of 1590 COVID-19 patients in China revealed that a significant ratio of 2.681 (95% CI: 1.424–5.048) underwent ICU admission, mechanical ventilation, or death [46].

A South Korean study found that pneumococcal and influenza vaccinations could contribute to the prevention of CAP and severe exacerbations in patients with COPD [47]. Portuguese research [48] and recent global initiative for chronic obstructive lung disease (GOLD) guidelines [49] have suggested that pneumococcal and influenza vaccination during the early stages of COPD may help maintain stable health conditions.

3.3. Asthma

Airway inflammation in patients with asthma may contribute to impaired immunity, with an increased predisposition to bacterial and viral infections [50]. A previous report described that this increased risk was driven by a greater prevalence of *S. pneumoniae* carriage and a disordered immune response due to bacterial exposure, impaired bacterial clearance, and suboptimal response to vaccination [51]. Based on the CDC Active Bacterial Surveillance Core data, it has been reported that patients with asthma have more than a 2-fold increased risk of invasive pneumococcal disease [52]. Other studies have also noted that the risk for participants with underlying asthma and concomitant pneumonia is more than 22% worse than in those with pneumonia alone [53]. In addition, a study in Spain concluded that the increased risk for hospitalization due to COVID-19 in patients with asthma was associated with comorbidities and mortality, especially among older patients [54].

3.4. Cardiovascular Disease (CVD)

CVD is the leading cause of morbidity and mortality worldwide, especially among the elderly [55]. Conventional culprits, such as smoking, obesity, hypertension, diabetes, dyslipidemia, influenza, and pneumonia, are considered potential CVD risk factors [56–58]. In the Cardiovascular Health Study that examined two community-based cohorts, the Atherosclerosis Risk in Communities data showed that most patients hospitalized for pneumonia recovered in one week [59]. However, an increased level of coagulation markers was detected in half of these patients at hospital discharge, indicating an increased risk of cardiovascular deaths [60].

The American College of Cardiology (ACC) reported that patients with underlying CVD were at higher risk of contracting COVID-19 and developing poor prognoses. Given the increased risk of secondary bacterial infection with COVID-19, the ACC/American Heart Association guidelines recommend that patients with CVD be up to date on their vaccines, especially the pneumococcal vaccine [61].

3.5. Chronic Heart Disease

Pneumococcal pneumonia places people with underlying chronic heart disease at substantial risk for an acute cardiac event, including myocardial infarction, severe arrhythmia, and new or worsening congestive heart failure [62]. Notably, patients with pneumococcal pneumonia and cardiac diseases had about 20% higher mortality than patients with pneumococcal pneumonia alone [63]. In a Danish study of 67,000 patients, patients with chronic heart failure had nearly double the risk of hospitalization with pneumonia than healthy
individuals [64]. In studies conducted in Wuhan, China, the prevalence of hypertension was significantly higher in patients with severe COVID-19 than in those with nonsevere conditions (38.7% vs. 22.2%) [65].

3.6. Chronic Kidney Disease (CKD)

CKD is unique compared to other risk groups since it has multiple predisposing factors that lead to pneumococcal infection [66,67]. According to the guidelines of the government of Canada, patients with chronic renal disease are at a higher risk of pneumococcal infection. Since bacterial and viral infections are a significant cause of morbidity and mortality in these patients or in those undergoing chronic dialysis (hemodialysis or peritoneal dialysis), they have recommended that patients undergoing dialysis should receive all routine vaccinations, including pneumococcal vaccines [68].

A study regarding CKD as a risk factor for COVID-19 mortality provided important information on the epidemiology of COVID-19 [1]. A previous review paper also suggested that patients with CKD, including those undergoing dialysis or who underwent a kidney transplant, should be included in COVID-19 vaccination trials since uremia and the use of immunosuppressive agents could potentially hamper vaccination responses [69].

3.7. Chronic Liver Disease (CLD)

CLD is one of the main risk factors for pulmonary complications in patients with pneumococcal CAP. Patients with severe chronic liver disease have impaired phagocyte function, defects in opsonizing antibodies, and consequent splenic dysfunctions. In addition, severe COVID-19 tends to increase the risk of developing gastrointestinal symptoms and abnormal liver function [70]. Mao et al. [71] analyzed findings from 12 studies (n = 1267) and showed the pooled prevalence of abnormal liver functions of 19%. Hepatic encephalopathy or regular alcohol intake can also lead to aspiration pneumonia, making alcoholism a risk factor for invasive pneumococcal disease [72]. In addition, the CDC has recommended pneumococcal vaccination for all adults with liver disease [73].

3.8. Diabetes

Patients with diabetes are vulnerable to infections because of the reduced response of T cells, neutrophil function, and the hyperglycemic environment that favors immune dysfunction [74–76]. For this reason, diabetes mellitus increases the patients’ susceptibility to infectious diseases, potentially increasing their morbimortality [74,75,77,78]. Diabetes mellitus, associated with the most frequent respiratory infections, is caused by S. pneumoniae [79], which can worsen pre-existing diabetes. In a U.S. cohort study, the risk of pneumococcal pneumonia in 18-year-old diabetic patients was from 2.5 to 3.1 times higher than that of healthy individuals of the same age [28,53].

During the COVID-19 era, strict management of blood glucose levels and cardiovascular risk factors is crucial for patients with diabetes mellitus [80] since COVID-19 can exacerbate inflammation and modify immune system responses, leading to poor glycemic control [81]. These mechanisms are now believed to contribute to the poor prognosis of COVID-19 patients with diabetes mellitus. In addition, the CDC [82] and Canadian Immunization Guide [72] have recommended that diabetic patients receive pneumococcal vaccines in this particular order: once as an adult before the age of 65 years, followed by two more doses when they are 65 years or older.

3.9. Cancer

Pneumonia in patients with cancer has been linked to higher mortality, increased severity of complications, prolonged length of hospitalization, and increased hospital-related expenses [83]. Based on the Japan Medical Data Center, the risk of invasive pneumococcal disease was higher in cancer patients than in healthy individuals of the same age [34]. S. pneumoniae, causing pneumococcal pneumonia, may have severe implications in patients with cancer, including a high risk for IPD, especially those with multiple myeloma and
lungs [84]. Thus, pneumococcal immunization is generally advised for all cancer patients [85].

According to the COVID-19 cohort research, a part of the international severe acute respiratory and emerging infection consortium that included hospitalized cancer patients in the UK, patients with cancer had a 40.5% risk of mortality compared to a 28.5% risk in those without cancer (HR: 1.62, 95% percent CI: 1.56–1.68) [86].

3.10. Smoking

Smoking may enhance the adherence of pneumococci to epithelial cells, increasing the risk for pneumococcal infections [87]. According to an Australian study, smokers are 3.7 times more likely to acquire S. pneumoniae than nonsmokers [88]. Large cohort research of 387,109 adults in the UK proved that smoking increased the risk of COVID-19. (RR = 1.42, 95% CI: 1.12–1.79) [89]. Another study also found that COVID-19 patients who smoked were more likely to have more severe conditions (RR = 1.4, 95% CI: 0.98–2.00) and a higher probability of being admitted into the ICU, requiring mechanical ventilation or dying, than nonsmokers (RR = 2.4, 95% CI: 1.43–4.04) [90]. Implementing smoking cessation programs and a pneumococcal vaccination schedule is necessary to decrease the burden of pneumococcal infections in these patients [91].

The cohort research conducted in Louisville [19] found that COPD patients had the most significant risk, with an annual incidence of 5832 per 100,000 individuals with COPD (Figure 1), followed by 3456 per 100,000 adults with CHF, 2034 per 100,000 adults with stroke, 1808 per 100,000 adults with diabetes, 822 per 100,000 current smoker adults, and 634 per 100,000 obese adults.

![Figure 1](image)

**Figure 1.** The impact of comorbidities on the incidence of patients hospitalized with community-acquired pneumonia (CAP). CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease.

4. Combined Infection with SARS-CoV-2 and S. pneumoniae

A common complication of respiratory viral disease is bacterial coinfection or secondary bacterial infection, which occurs during or after an infectious disease caused by another pathogenic virus [13]. These infections can worsen clinical outcomes and disease severity, consequently increasing morbidity and mortality [92].

Coinfection has been reported in patients with SARS and MERS [93,94], and similarly, bacterial coinfections have also been known as prevalent complications in COVID-19 patients [95]. Reports show that SARS-CoV-2 may strengthen bacterial colonization and attachment to the host tissue, and the concurrent infections may result in irreversible tissue damage and enhanced pathophysiology [94]. Furthermore, several studies have revealed that the prevalence of COVID-19-associated co/secondary infection is as high as 45.0% [93].

---

**References**

[19] website: 387,109 adults in the UK proved that smoking increased the risk of COVID-19. (RR = 1.42, 95% CI: 1.12–1.79) [89]. Another study also found that COVID-19 patients who smoked were more likely to have more severe conditions (RR = 1.4, 95% CI: 0.98–2.00) and a higher probability of being admitted into the ICU, requiring mechanical ventilation or dying, than nonsmokers (RR = 2.4, 95% CI: 1.43–4.04) [90]. Implementing smoking cessation programs and a pneumococcal vaccination schedule is necessary to decrease the burden of pneumococcal infections in these patients [91].

The cohort research conducted in Louisville [19] found that COPD patients had the most significant risk, with an annual incidence of 5832 per 100,000 individuals with COPD (Figure 1), followed by 3456 per 100,000 adults with CHF, 2034 per 100,000 adults with stroke, 1808 per 100,000 adults with diabetes, 822 per 100,000 current smoker adults, and 634 per 100,000 obese adults.

![Figure 1](image)

**Figure 1.** The impact of comorbidities on the incidence of patients hospitalized with community-acquired pneumonia (CAP). CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease.

4. Combined Infection with SARS-CoV-2 and S. pneumoniae

A common complication of respiratory viral disease is bacterial coinfection or secondary bacterial infection, which occurs during or after an infectious disease caused by another pathogenic virus [13]. These infections can worsen clinical outcomes and disease severity, consequently increasing morbidity and mortality [92].

Coinfection has been reported in patients with SARS and MERS [93,94], and similarly, bacterial coinfections have also been known as prevalent complications in COVID-19 patients [95]. Reports show that SARS-CoV-2 may strengthen bacterial colonization and attachment to the host tissue, and the concurrent infections may result in irreversible tissue damage and enhanced pathophysiology [94]. Furthermore, several studies have revealed that the prevalence of COVID-19-associated co/secondary infection is as high as 45.0% [93].
and that half of mortalities occurred due to secondary bacterial infections [96]. Additionally, COVID-19 patients with a bacterial coinfection were 5.82 times more likely to die than COVID-19 patients who did not have a coinfection [97].

Another crucial issue occurs when superinfections accompany COVID-19. One study reported that 24% of COVID-19 patients had superinfections, were described to be more severely ill, and had a higher risk of mortality. It appeared to be mainly due to the resistance of the superinfection to previously used antibiotics. Although the actual incidence of bacterial superinfections in COVID-19 is unknown so far, superinfections are expected to pose a significant challenge in the management of COVID-19 patients [98].

Key findings from recent studies have consistently shown a positive association between co/secondary bacterial infection or superinfection and an increased risk of mortality among COVID-19 patients [99,100].

5. Recommendations for Two Vaccine-Preventable Diseases (VPDs)

5.1. Impact of Pneumococcal Vaccines in COVID-19

Vaccination is the most beneficial health policy for improving public health and reducing the impact of infectious disease. In particular, the current public health burden of S. pneumoniae infection has been reduced by vaccine tools demonstrated by the results of administering pneumococcal polysaccharide vaccine (PPSV23) and pneumococcal conjugate vaccine (PCV13) in adults [101]. PPSV23 and PCV13 have different immunological mechanisms to activate antipneumonia immune responses. PPSV23, composed of purified polysaccharides, triggers a T-cell-independent activation to activate B cells [102]. However, the memory B cells generated during the response of T-cell independent PPSV23 are short-lived and create a week antibody production upon re-exposure to the antigen [103]. Thus, vaccines containing capsular polysaccharides alone, such as PPSV23, have low immunogenicity in immunocompromised patients [104].

A nontoxic CRM197 carrier protein conjugated in PCV13 triggers a T-cell-dependent response. In contrast to PPSV23, the protein-polysaccharide conjugate (PCV13) binds to B cell receptors. The subsequent signaling promotes the generation and proliferation of long-lived memory B cells that secrete isotype-switched and affinity-maturated antibodies [105]. A randomized, double-blind, placebo-controlled trial (the Community-Acquired Pneumonia Immunization Trial in Adults) in the Netherlands involving 84,496 adults aged ≥ 65 years from 2008 to 2013 reported a 45.5% efficacy for PCV13 against all vaccine-type pneumococcal CAP, a 45% efficacy against vaccine-type nonbacteremic pneumococcal CAP, and a 75% efficacy against vaccine-type IPD [106]. The CDC recommends PCV13 for all children < 2 years of age and children aged ≥ 2 years with certain medical conditions. Adults aged ≥ 65 years can select whether to get PCV13 or PPSV23 vaccinations, whereas individuals between 2 and 64 years of age are only eligible if they have certain medical conditions [107]. Currently, many researchers are looking at the possibility of preventive methods that can lower COVID-19 mortality and morbidity. Despite the unknown interaction of pneumococcal disease and COVID-19 [108], the WHO has announced that vaccines against pneumonia, including pneumococcal vaccines and the Haemophilus influenza type B (Hib) vaccine, do not protect against any types of pneumonia caused by coronaviruses, including COVID-19 [109,110].

However, a recent Mayo Clinic study reported powerful associations between pneumococcal vaccination and COVID-19 immunity [111,112], reporting that older PCV13-vaccinated adults acquired certain pneumococcal strains and experienced a 35% lower risk of COVID-19 infection than the unvaccinated adults. In contrast, an alternative pneumococcal vaccine (PPSV23) prevented severe pneumococcal disease but did not generate the same immunity to block bacterial acquisitions [113]. Another randomized controlled trial with children and adults [114–117] found PCVs to confer 23 to 49% protection against pneumonia-associated respiratory viruses, including human coronavirus [115,116], supporting the etiologic involvement of pneumococci in virus-associated respiratory disease. Lewnard et al. [113] estimated adjusted hazard ratios (aHRs) for the association of COVID-
19 with PCV13 from the data accumulated among 531,033 adults and provided convincing results showing that prior pneumococcal vaccination reduced the clinical outcomes of COVID-19. Another study analyzed data from the 51 nations and found a strong negative correlation between pneumococcal vaccination and COVID-19 case and death rates [118].

Direct prevention may be difficult despite these findings since the pneumococcal vaccine is not a “dedicated” vaccine for COVID-19. Therefore, the question arises whether bacterial vaccines can prevent the transmission of the virus, given that the pneumococcal vaccine has been reported to avoid a substantial burden of targeted diseases and mortality among adults at risk [119]. The CDC Advisory Committee on Immunization Practices recommends the use of the 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) for adults aged ≥ 19 years (Table 2) [120].

5.2. Recommendations of Pneumococcal Vaccine for Reducing the Risk of COVID-19

In most high-income countries, such as the United States, United Kingdom, Sweden, Germany, France, Norway, and Italy, the pneumococcal vaccination rate for adults is high because vaccination is recommended and free for those over 65 years of age. However, vaccination is just advised for older adults in several countries, such as Switzerland, South Korea, and Australia. The rate is rare even in low- and middle-income countries [121]. Therefore, there are several recommendations that clinics and patients can implement to reduce the risk of COVID-19. First and foremost, patients should be immunized to reduce the risk of preventable coinfections with other viruses. Specifically, they should receive vaccines against *S. pneumoniae* (PCV13 and PPSV23) [122]. Such vaccinations could stimulate an immune response in older adults; although the data are not fully supportive of this hypothesis, pneumococcal vaccinations could reduce the risk and potentially severe infections, including COVID-19 [123–125]. Thindwa et al. [119] estimated COVID-19 mortality associated with pneumococcal coinfection and reported that PPSV23 in older adults could reduce potentially pneumococcal-attributable COVID-19 morbidity and mortality.

Data analysis of the EPI COVID-19 survey indicates that pneumococcal vaccinations and/or coadministration of influenza vaccines can reduce the risk of being infected with SARS-CoV-2, although further supporting evidence is still required to confirm this possibility. Considering that multiple respiratory coinfections can frequently lead to fatal respiratory failure, especially in older age, some research claims collaborative public health programs to enhance antipneumococcal and anti-influenza vaccination campaigns. Therefore, special attention should be paid to the individuals in the most vulnerable categories of risk factors to reduce severe COVID-19 prognosis.

The Pan American Health Organization guides the conduct of immunization programs in the context of the COVID-19 pandemic, recognizing that healthcare systems face a rapid increase in demands. If healthcare systems become overwhelmed, both mortality and morbidity from preventable and treatable conditions, such as VPDs, increase dramatically [126]. Any disruption of health services, even for a short time, will increase the number of individuals susceptible to infections, increasing the likelihood of VPD outbreaks. Such outbreaks may result in health crises and an increased burden on health systems, which are already strained with COVID-19 response operations. Since immunization is an essential component of health services, routine immunization programs should be maintained as long as COVID-19 response measures allow. Furthermore, one of the guiding principles for immunization programs during the COVID-19 pandemic must include prioritizing pneumococcal and seasonal influenza vaccines for vulnerable population groups [127].
### Table 2. Recommendations for the 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) among adults aged ≥ 19 years.

| Medical Indication Group | Specific Underlying Medical Condition | PCV13 for Persons Aged ≥ 19 Years | PPSV23 * for Persons Aged 19–64 Years | PCV13 for Persons Aged ≥ 65 Years | PPSV23 for Persons Aged ≥ 65 Years |
|--------------------------|----------------------------------------|-----------------------------------|----------------------------------------|-----------------------------------|-----------------------------------|
| None                     | None of the below                      | No recommendation                 | No recommendation                      | Based on shared clinical decision-making † | 1 dose; if PCV13 has been administered, then administer PPSV23 ≥ 1 year after PCV13 |
| Immunocompetent persons  | Alcoholism                             | No recommendation                 | 1 dose                                 | Based on shared clinical decision-making † | 1 dose; if PCV13 has been administered, then administer PPSV23 ≥ 1 year after PCV13 and ≥ 5 years after any PPSV23 at age < 65 years |
|                          | Chronic heart disease §                |                                   |                                        |                                   |                                   |
|                          | Chronic liver disease                  |                                   |                                        |                                   |                                   |
|                          | Chronic lung disease ¶                 |                                   |                                        |                                   |                                   |
|                          | Cigarette smoking                      |                                   |                                        |                                   |                                   |
|                          | Diabetes mellitus                      |                                   |                                        |                                   |                                   |
|                          | Cochlear implant                       | 1 dose                            | 1 dose ≥ 8 weeks after PCV13           | 1 dose if no previous PCV13 vaccination | 1 dose ≥ 8 weeks after PCV13 and ≥ 5 years after any PPSV23 at < 65 years |
|                          | CSF leak                               |                                   |                                        |                                   |                                   |
| Immunocompromised persons| Congenital or acquired asplenia        | 1 dose                            | 2 doses, 1st dose ≥ 8 weeks after PCV13 and 2nd dose ≥ 5 years after first PPSV23 dose | 1 dose if no previous PCV13 vaccination | dose ≥ 8 weeks after PCV13 and ≥ 5 years after any PPSV23 at < 65 years |
|                          | Sickle cell disease/other hemoglobinopathies |                                   |                                        |                                   |                                   |
|                          | Chronic renal failure                  |                                   |                                        |                                   |                                   |
|                          | Congenital or acquired immunodeficiencies ** |                                   |                                        |                                   |                                   |
|                          | Generalized malignancy                 |                                   |                                        |                                   |                                   |
|                          | HIV infection                          |                                   |                                        |                                   |                                   |
|                          | Hodgkin disease                        |                                   |                                        |                                   |                                   |
|                          | Iatrogenic immunosuppression ††       |                                   |                                        |                                   |                                   |
|                          | Leukemia                               |                                   |                                        |                                   |                                   |
|                          | Lymphoma                               |                                   |                                        |                                   |                                   |
|                          | Multiple myeloma                       |                                   |                                        |                                   |                                   |
|                          | Nephrotic syndrome                     |                                   |                                        |                                   |                                   |
|                          | Solid-organ transplant                 |                                   |                                        |                                   |                                   |

ACIP = Advisory Committee on Immunization Practices; CSF = cerebrospinal fluid; HIV = human immunodeficiency virus. * Refers only to adults aged 19–64 years. All adults aged ≥ 65 years should receive 1 dose of PPSV23 ≥ 5 years after any previous PPSV23 dose regardless of the previous history of vaccination with pneumococcal vaccine. No additional doses of PPSV23 should be administered following the dose administered at age ≥ 65 years. † Recommendations that changed in 2019. § Includes congestive heart failure and cardiomyopathies. ¶ Includes chronic obstructive pulmonary disease, emphysema, and asthma. ** Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease). †† Diseases requiring treatment with immunosuppressive drugs including long-term systemic corticosteroids and radiation therapy.
It was especially timely guidance since influenza and pneumococcal vaccines were easily accessible when public health officials were challenged with a lack of effective COVID-19 vaccines during the 2020 autumn–winter season [128,129]. Spain [130] has also indicated that it is essential for patients with CKD, similar to patients with CVD, to remain up to date with their vaccinations, including the pneumococcal vaccine, given the increased risk of secondary bacterial infection with COVID-19. Moreover, Canada’s Ontario Ministry of Health [131] said the ongoing pneumococcal vaccination for the underlying conditions mentioned by the CDC should be prioritized.

Influenza and pneumococcal vaccines continue to be recommended for immuno-suppressed individuals by the American Red Cross, New York City Health Department, European AIDS Clinical Society [132], and Australian Government Department regardless of the threat of COVID-19.

6. Conclusions

The new viral infection caused by SARS-CoV-2, popularly known as COVID-19, has spread worldwide, becoming the most dangerous pandemic threatening the global health system over the decades. We found that most fatalities during the past century’s influenza pandemics were associated with bacterial co/secondary infections. Similarly, reports have stated that bacterial coinfection is predominant in COVID-19 patients, with a co/secondary infection prevalence of up to 45.0%. This challenge needs close attention to the effect of concurrent infections, including co/secondary bacterial infections and superinfections, on the morbidity and mortality of COVID-19 patients. Based on previous studies, the predominant coinfection during the influenza pandemics since the late 1800s was by *S. pneumoniae*. During the COVID-19 pandemic, *S. pneumoniae* remains the most common coinfecting bacteria (59.5% coinfection rate of *S. pneumoniae* in coinfection cases).

Studies have shown that bacterial coinfection decreases immune function and increases the mortality of COVID-19 patients, with a 7.8-fold higher mortality in coinfected patients than in patients with only pneumonia. Half of the recorded COVID-19 mortalities were coinfected cases, and COVID-19 mortality due to pneumonia in patients > 65 years of age accounted for 23% of recorded mortalities because the weakening of immune function caused by COVID-19 remains a high-risk factor for pneumococcal disease. A detailed investigation of the impact of risk factors and underlying medical conditions on COVID-19 and pneumococcal diseases, such as old age, cancer, diabetes mellitus, asthma, smoking, and chronic diseases related to the heart, kidneys, and liver, revealed that pneumococcal disease and COVID-19 have similar risk factors.

Underlying medical conditions of patients of any age with *S. pneumoniae* increase the risk of severe illness; COVID-19 is now considered a primary risk factor for pneumococcal pneumonia and invasive pneumococcal disease. Given all these findings, pneumococcal vaccination during the COVID-19 pandemic is more critical than ever. To that end, we have presented positive studies of pneumococcal vaccination in patients with COVID-19 and underlying medical conditions in this review. Although the WHO has announced that bacterial vaccination does not protect against COVID-19 pneumonia, we have shown the correlation effect between pneumococcal disease and COVID-19 in preventing increased morbidities and mortalities by co/secondary infections and superinfections.

To strengthen the global health system in the campaign against COVID-19, we have presented why pneumococcal vaccination has a significant role in the current pandemic setting. This review supports the recommendation for pneumococcal disease vaccination and proffers the consequent relief from the COVID-19 pandemic.

**Author Contributions:** Conceptualization, J.S. and H.I.; methodology, J.S.; software, U.S.; validation, H.I., H.C.; formal analysis, H.C.; investigation, H.C.; resources, U.S.; data curation, H.I.; writing—original draft preparation, H.I.; writing—review and editing, J.S.; visualization, J.S.; supervision, U.S.; project administration, H.C.; funding acquisition, U.S. All authors have read and agreed to the published version of the manuscript.
**References**

1. Williamson, E.J.; Walker, A.J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C.E.; Curtis, H.J.; Mehrkar, A.; Evans, D.; Inglesby, P. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020, 584, 430–436. [CrossRef] [PubMed]

2. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 15 December 2021).

3. Maggi, S. Vaccination and healthy aging. *Expert Rev. Vaccines* 2010, 9, 3–6. [CrossRef] [PubMed]

4. Sanyaolu, A.; Okorie, C.; Marinkovic, A.; Patidar, R.; Yoonsi, K.; Desai, P.; Hosein, Z.; Padda, I.; Mangat, J.; Altaf, M. Comorbidity and its Impact on Patients with COVID-19. *SN Compr. Clin. Med.* 2020, 2, 1069–1076. [CrossRef] [PubMed]

5. Kiani, F.Z.; Ahmadi, A. Prevalence of different comorbidities in chronic obstructive pulmonary disease among Shahrekord PERSIAN cohort study in southwest Iran. *Sci. Rep.* 2021, 11, 1548. [CrossRef]

6. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet* 2020, 395, 1054–1062. [CrossRef]

7. Maddaloni, E.; Buzzetti, R. COVID-19 and diabetes mellitus: Unveiling the interaction of two pandemics. *Diabetes Metab. Res. Rev.* 2020, 36, e3213321. [CrossRef]

8. Xu, L.; Mao, Y.; Chen, G. Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: A systematic review and meta-analysis. *Aging* 2020, 12, 12410. [CrossRef]

9. Jordan, R.E.; Adab, P.; Cheng, K. COVID-19: Risk factors for severe disease and death. *BMJ* 2020, 368, m1198. [CrossRef]

10. Fang, X.; Li, S.; Yu, H.; Wang, P.; Zhang, Y.; Chen, Z.; Li, Y.; Cheng, L.; Li, W.; Jia, H. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: A systematic review and meta-analysis. *Aging* 2020, 12, 12493. [CrossRef] [PubMed]

11. Sultana, J.; Mazzaglia, G.; Luxi, N.; Cancellieri, A.; Capuano, A.; Ferrajolo, C.; de Waure, C.; Ferlazzo, G.; Trifirò, G. Potential effects of vaccinations on the prevention of COVID-19: Rationale, clinical evidence, risks, and public health considerations. *Expert Rev. Vaccines* 2020, 19, 919–936. [CrossRef]

12. Joseph, C.; Togawa, Y.; Shindo, N. Bacterial and viral infections associated with influenza. *Influenza Other Respir. Viruses* 2013, 7, 105–113. [CrossRef]

13. Morris, D.E.; Cleary, D.W.; Clarke, S.C. Secondary bacterial infections associated with influenza pandemics. *Front. Microbiol.* 2017, 8, 1041. [CrossRef]

14. Wang, L.; Fu, J.; Liang, Z.; Chen, J. Prevalence and serotype distribution of nasopharyngeal carriage of *Streptococcus pneumoniae* in China: A meta-analysis. *BMC Infect. Dis.* 2017, 17, 765. [CrossRef] [PubMed]

15. Aykac, K.; Oszurecki, Y.; Cura Yayla, B.C.; Evren, K.; Lacinel Gurlevik, S.; Oygar, P.; Alp, A.; Cengiz, A.B. Pneumococcal carriage in children with COVID-19. *Hum. Vaccines Immunother.* 2021, 17, 1628–1634. [CrossRef]

16. Rodriguez-Nava, G.; Yanez-Bello, M.A.; Treilles-Garcia, D.P.; Chung, C.W.; Egoryan, G.; Friedman, H.J. A retrospective study of coinfection of SARS-CoV-2 and *Streptococcus pneumoniae* in 11 hospitalized patients with severe COVID-19 pneumonia at a single center. *Med. Sci. Monit. Int. Med. J. Exp. Clin. Res.* 2020, 26, e928754-1. [CrossRef] [PubMed]

17. Lozano, R.; Naghv, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012, 380, 2095–2128. [CrossRef]

18. Mathers, C. *The Global Burden of Disease: 2004 Update*; World Health Organization: Geneva, Switzerland, 2008.

19. Ramirez, J.A.; Wiemken, T.L.; Peyrani, P.; Arnold, F.W.; Kelley, R.; Mattingly, W.A.; Nakamatsu, R.; Pena, S.; Guinn, B.E.; Furmanek, S.P. Adults hospitalized with pneumonia in the United States: Incidence, epidemiology, and mortality. *Clin. Infect. Dis.* 2017, 65, 1806–1812. [CrossRef]

20. McLaughlin, J.M.; McGinnis, J.J.; Tan, L.; Mercatante, A.; Fortuna, J. Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013. *J. Prim. Prev.* 2015, 36, 259–273. [CrossRef]

21. Sakamoto, A.; Chanyasanha, C.; Sujirarat, D.; Matsumoto, N.; Nakazato, M. Factors associated with pneumococcal vaccination in elderly people: A cross-sectional study among elderly club members in Miyakonojo City, Japan. *BMC Public Health* 2018, 18, 1172. [CrossRef] [PubMed]

22. CDC. Assessing Risk Factors for Severe COVID-19 Illness. Available online: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/assessing-risk-factors.html (accessed on 30 November 2021).

23. World Health Organization. *COVID-19 Clinical Management: Living Guidance*, 25 January 2021; World Health Organization: Geneva, Switzerland, 2021.
24. CDC. People with Certain Medical Conditions. Available online: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html (accessed on 13 May 2021).

25. CDC. Evidence Updated to List the Following Medical Conditions That Increase a Person’s Risk of Severe Illness from COVID-19; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2021.

26. World Health Organization. Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease is Suspected: Interim Guidance, 1 March 2020; World Health Organization: Geneva, Switzerland, 2020.

27. CDC. Pneumococcal Disease: Risk Factors and Transmission. Available online: https://www.cdc.gov/pneumococcal/about/risk-transmission.html (accessed on 1 September 2021).

28. Shea, K.M.; Edelsberg, J.; Weycker, D.; Farkouh, R.A.; Strutton, D.R.; Pelton, S.I. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect. Dis. 2014, 1, ofu024. [CrossRef]

29. Australian Government, Department of Health, People at Higher Risk of Coronavirus (COVID-19). Available online: https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/ongoing-support-during-coronavirus-covid-19/what-you-need-to-know-about-coronavirus-covid-19/people-at-higher-risk-of-coronavirus-covid-19 (accessed on 7 July 2021).

30. Gonzalez-Romo, F.; Picazo, J.J.; García Rojas, A.; Labrador Horrillo, M.; Barrios, V.; Magro, M.C.; Gregorio, P.G.; de la Cámara, R.; Rodríguez, A.; Barberán, J. Consenso sobre la vacunación anti-neumocócica en el adulto por riesgo de edad y patología de base. Actualización 2017. Rev. Esp. Quimioter. 2017, 30, 142–168. [PubMed]

31. Government of Canada, Coronavirus Disease (COVID-19): Prevention and Risks. Available online: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/prevention-risks.html (accessed on 16 August 2021).

32. Zhang, D.; Petigara, T.; Yang, X. Clinical and economic burden of pneumococcal disease in US adults aged 19–64 years with chronic or immunocompromising diseases: An observational database study. BMC Infect. Dis. 2018, 18, 436. [CrossRef]

33. Haut Conseil de la Santé Publique. Infections Invasives à Pneumocoque: Recommandations Vaccinales Pour les Personnes à Risque. 2013. Available online: https://www.hcsp.fr/Explore.cgi/AvisRapportsDomaine?clefr=355 (accessed on 1 September 2021).

34. Imai, K.; Petigara, T.; Kohn, M.A.; Nakashima, K.; Aoshima, M.; Shito, A.; Kanazu, S. Risk of pneumococcal diseases in adults with underlying medical conditions: A retrospective, cohort study using two Japanese healthcare databases. BMJ Open 2018, 8, e018553. [CrossRef] [PubMed]

35. Lee, M.S.; Oh, J.Y.; Kang, C.-I.; Kim, E.S.; Park, S.; Rhee, C.K.; Jung, J.Y.; Jo, K.-W.; Heo, E.Y.; Park, D.-A.; et al. Guideline for Antibiotic Use in Adults with Community-acquired Pneumonia. Infect. Chemother. 2018, 50, 160–198. [CrossRef]

36. Rivero-Calle, I.; Cebeý-López, M.; Pardo-Seco, J.; Yuste, J.; Redondo, E.; Vargas, D.A.; Mascarós, E.; Díaz-Maroto, J.L.; Linare-Rufo, M.; Jimeno, I. Lifestyle and comorbid conditions as risk factors for community-acquired pneumonia in outpatient adults (NEUMO-ES-RISK project). BMJ Open Respir. Res. 2019, 6, e000359. [CrossRef]

37. Vinogradova, Y.; Hippisley-Cox, J.; Coupland, C. Identification of new risk factors for pneumonia: Population-based case-control study. Br. J. Gen. Pract. 2009, 59, e329–e338. [CrossRef]

38. Public Health England. Pneumococcal: The Green Book, Chapter 25; Public Health England Government: London, UK, 2020.

39. O’Brien, D.G.K.L. Harrison’s Principles of Internal Medicine; McGraw-Hill Education: New York, NY, USA, 2018.

40. Fine, M.J.; Smith, M.A.; Carson, C.A.; Mutha, S.S.; Sankey, S.S.; Weissfeld, L.A.; Kapoor, W.N. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996, 275, 134–141. [CrossRef]

41. Örtqvist, Å.; Hedlund, J.; Kalin, M. Streptococcus pneumoniae: Epidemiology, risk factors, and clinical features. In Seminars in Respiratory and Critical Care Medicine; Thieme Medical Publishers, Inc.: New York, NY, USA, 2005; pp. 563–574.

42. Public Health England. Disparities in the Risk and Outcomes of COVID-19; Public Health England Government: London, UK, 2020.

43. CDC. Menu of State Long-Term Care Facility Pneumococcal Vaccination Laws. Available online: https://www.cdc.gov/phlp/publications/topic/menus/ltcpneumo/index.html (accessed on 28 February 2021).

44. World Health Organization. Infection Prevention and Control Guidance for Long-Term Care Facilities in the Context of COVID-19: Interim Guidance, 21 March 2020; World Health Organization: Geneva, Switzerland, 2020.

45. Qureshi, H.; Sharafkhaneh, A.; Hanania, N.A. Chronic obstructive pulmonary disease exacerbations: Latest evidence and clinical implications. Thor. Adv. Chronic Dis. 2014, 5, 212–227. [CrossRef] [PubMed]

46. Guan, W.-J.; Liang, W.-H.; Zhao, Y.; Liang, H.-R.; Chen, Z.-S.; Li, Y.-M.; Liu, X.-Q.; Chen, R.-C.; Tang, C.-L.; Wang, T. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur. Respir. J. 2020, 55, 2000547. [CrossRef]

47. Yoon, H.K.; Park, Y.-B.; Rhee, C.K.; Lee, J.H.; Oh, Y.-M.; Committee of the Korean COPD Guideline. Summary of the Chronic obstructive Pulmonary Disease Clinical Practice Guideline Revised in 2014 by the Korean Academy of Tuberculosis and Respiratory Disease. Tuberc. Respir. Dis. 2017, 80, 230–240. [CrossRef]

48. Froes, F.; Roche, N.; Blasi, F. Pneumococcal vaccination and chronic respiratory diseases. Int. J. Chronic Obs. Pulmon. Dis. 2017, 12, 3457–3468. [CrossRef] [PubMed]

49. Singh, D.; Agusti, A.; Anzueto, A.; Barnes, P.; Bourbeau, J.; Celli, B.; Criner, G.; Frith, P.; Halpin, D.; Han, M.; et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The GOLD science committee report 2019. Eur. Respir. J. 2019, 18, 1900164. [CrossRef] [PubMed]

50. Gillissen, A.; Paparoupa, M. Inflammation and infections in asthma. Clin. Respir. J. 2015, 9, 257–269. [CrossRef]
51. Zaidi, S.R.; Blakey, J.D. Why are people with asthma susceptible to pneumonia? A review of factors related to upper airway bacteria. *Respiratory* 2019, 24, 423–430. [CrossRef] [PubMed]

52. Talbot, T.R.; Hartert, T.V.; Mitchel, E.; Halasa, N.B.; Arbogast, P.G.; Poehling, K.A.; Schaffner, W.; Craig, A.S.; Griffin, M.R. Asthma as a risk factor for invasive pneumococcal disease. *N. Engl. J. Med.* 2005, 352, 2082–2090. [CrossRef]

53. Wyrwich, K.W.; Yu, H.; Sato, R.; Strutton, D.; Powers, J.H. Community-acquired pneumonia: Symptoms and burden of illness at diagnosis among US adults aged 50 years and older. *Patient-Patient-Cent. Outcomes Res.* 2013, 6, 125–134. [CrossRef]

54. Izquierdo, J.L.; Almonacid, C.; González, Y.; Del Rio-Bermúdez, C.; Ancochea, J.; Cárdenas, R.; Soriano, J.B. The Impact of COVID-19 on Patients with Asthma. *Eur. Respir. J.* 2020, 57, 2003142. [CrossRef]

55. The National Heart, Lung and Blood Institute. *Morbidity and Mortality: 2012 Chartbook on Cardiovascular, Lung and Blood Diseases*; US Department of Health and Human Services; Public Health Service, National Institutes of Health: Bethesda, MD, USA, 2012.

56. Wong, N.D. Epidemiological studies of CHD and the evolution of preventive cardiology. *Nat. Rev. Cardiol.* 2014, 11, 276. [CrossRef]

57. Warren-Gash, C.; Smeeth, L.; Hayward, A.C. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: A systematic review. *Lancet Infect. Dis.* 2009, 9, 601–610. [CrossRef]

58. Bova, I.; Borstein, N.; Korczyn, A. Acute infection as a risk factor for ischemic stroke. *Stroke* 1996, 27, 2204–2206. [CrossRef]

59. Yende, S.; D'Angelo, G.; Kellum, J.A.; Welch, J.; Fine, J.; Welch, R.D.; Kong, L.; Carter, M.; Angus, D.C. Inflammatory markers at hospital discharge predict subsequent mortality after sepsis and nosocomial pneumonia. *Am. J. Respir. Crit. Care Med.* 2008, 177, 1242–1247. [CrossRef]

60. Corrales-Medina, V.F.; Alvarez, K.N.; Weissfeld, L.A.; Angus, D.C.; Chirinos, J.A.; Chang, C.C.; Newman, A.; Loehr, L.; Folsom, A.R.; Elkind, M.S.; et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. *JAMA* 2015, 313, 264–274. [CrossRef]

61. Story, A.N. ACC Clinical Bulletin Focuses on Cardiac Implications of Coronavirus (COVID-19). Available online: https://www.acc.org/latest-in-cardiology/articles/2020/02/13/12/42/acc-clinical-bulletin-focuses-on-cardiac-implications-of-coronavirus-2019-ncov (accessed on 13 February 2021).

62. Friedberg, C.K. Diseases of the Heart. *Acad. Med.* 1950, 25, 159.

63. Bennett, J.E.; Dolin, R.; Blaser, M.J. *Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases: 2-Volume Set*; Elsevier Health Sciences: London, UK, 2014; Volume 2.

64. Mor, A.; Thomsen, R.W.; Ulrichsen, S.P.; Sørensen, H.T. Chronic heart failure and risk of hospitalization with pneumonia: A population-based study. *Eur. J. Intern. Med.* 2013, 24, 349–353. [CrossRef] [PubMed]

65. The National Advisory Committee on Immunization. *Pneumococcal Vaccine. Canadian Immunization Guide*; Public Health Agency of Canada (PHAC): Ottawa, ON, USA, 2016.

66. Vaziri, N.; Pahl, M.; Crum, A.; Norris, K. Effect of uremia on structure and function of immune system. *J. Ren. Nutr.* 2012, 22, 149–156. [CrossRef]

67. Kato, S.; Chmielewski, M.; Honda, H.; Pecoits-Filho, R.; Matsuo, S.; Yuzawa, Y.; Tranaeus, A.; Stenvinkel, P.; Lindholm, B. Aspects of immune dysfunction in end-stage renal disease. *Clin. J. Am. Soc. Nephrol.* 2008, 3, 1526–1533. [CrossRef] [PubMed]

68. Immunization of Immunocompromised Persons: Canadian Immunization Guide. Available online: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-7-immunization-persons-with-chronic-diseases.html (accessed on 2 May 2021).

69. Gansevoort, R.T.; Hillbrands, L.B. CKD is a key risk factor for COVID-19 mortality. *Nat. Rev. Nephrol.* 2020, 16, 705–706. [CrossRef] [PubMed]

70. Guan, W.-J.; Ni, Z.-Y.; Hu, Y.; Liang, W.-H.; Ou, C.-Q.; He, J.-X.; Liu, L.; Shan, H.; Lei, C.-L.; Hui, D.S.C.; et al. Clinical characteristics of coronavirus disease 2019 in China. *N. Engl. J. Med.* 2020, 382, 1708–1720. [CrossRef] [PubMed]

71. Mao, R.; Qiu, Y.; He, J.-S.; Tan, J.-Y.; Li, X.-H.; Liang, J.; Shen, J.; Zhu, L.-R.; Chen, Y.; Iacucci, M.; et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: A systematic review and meta-analysis. *Lancet Gastroenterol. Hepatol.* 2020, 5, 667–678. [CrossRef]

72. Immunization of Persons with Chronic Diseases: Canadian Immunization Guide. Available online: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-7-immunization-immunocompromised-persons.html (accessed on 23 November 2021).

73. Gansevoort, R.T.; Hillbrands, L.B. CKD is a key risk factor for COVID-19 mortality. *Nat. Rev. Nephrol.* 2020, 16, 705–706. [CrossRef] [PubMed]

74. Guan, W.-J.; Ni, Z.-Y.; Hu, Y.; Liang, W.-H.; Ou, C.-Q.; He, J.-X.; Liu, L.; Shan, H.; Lei, C.-L.; Hui, D.S.C.; et al. Clinical characteristics of coronavirus disease 2019 in China. *N. Engl. J. Med.* 2020, 382, 1708–1720. [CrossRef] [PubMed]

75. Muller, L.M.; Gorter, K.J.; Hak, E.; Goudzwaard, W.L.; Schellevis, F.G.; Hoepelman, A.I.; Rutten, G.E. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. *Clin. Infect. Dis.* 2005, 41, 281–288. [CrossRef] [PubMed]

76. Peleg, A.Y.; Weeraratna, T.; McCarthy, J.S.; Davis, T.M. Common infections in diabetes: Pathogenesis, management and relationship to glycaemic control. *Diabetes Metab. Res. Rev.* 2007, 23, 3–13. [CrossRef] [PubMed]

77. Vardakas, K.Z.; Siempos, I.I.; Falagas, M.E. Diabetes mellitus as a risk factor for nosocomial pneumonia and associated mortality. *Diabet. Med.* 2007, 24, 1168–1171. [CrossRef]
81. Lim, S.; Bae, J.H.; Kwon, H.-S.; Nauck, M.A. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. *Nat. Rev. Endocrinol.* 2021, 17, 11–30. [CrossRef]
82. Control CFD. Prevention. Influenza and pneumococcal vaccination coverage among persons aged ≥ or = 65 years and persons aged 18–64 years with diabetes or asthma—United States, 2003. *MMWR Morb. Mortal. Wkly. Rep.* 2004, 53, 1007–1012.
83. Semenov, Y.R.; Starmer, H.M.; Gourin, C.G. The effect of pneumonia on short-term outcomes and cost of care after head and neck cancer surgery. *Laryngoscope* 2012, 122, 1994–2004. [CrossRef]
84. Lipsky, B.A.; Boyko, E.J.; Inui, T.S.; Koepsell, T.D. Risk factors for acquiring pneumococcal infections. *Arch. Intern. Med.* 1986, 146, 2179–2185. [PubMed]
85. Pai, S. Vaccinations for Cancer Patients: What to Know. Available online: https://www.mdanderson.org/cancerwise/vaccinations-for-cancer-patients--what-to-know.h00-159149190.html (accessed on 16 October 2021).
86. Docherty, A.; Harrison, E.; Green, C.; Hardwick, H.; Pius, R.; Norman, L.; Holden, K.; Read, J.; Dondleling, F.; Carson, G.; et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. *medRxiv* 2020, 1, 20076042. [CrossRef]
87. Raman, A.S.; Swinburne, A.J.; Fedullo, A.J. Pneumococcal adherence to the buccal epithelial cells of cigarette smokers. *Chest* 1983, 83, 23–27. [CrossRef]
88. Jacups, S.P.; Cheng, A. The epidemiology of community acquired bacteraemic pneumonia, due to *Streptococcus pneumoniae*, in the top end of the Northern Territory, Australia—Over 22 years. *Vaccine* 2011, 29, 5386–5392. [CrossRef]
89. Hamer, M.; Kivimäki, M.; Gale, C.R.; Batty, G.D. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK. *Brain Behav. Immun.* 2020, 87, 184–187. [CrossRef] [PubMed]
90. Vos, Q.; Lees, A.; Wu, Z.-Q.; Snapper, C.; Mond, J. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. *Immunol. Rev.* 2000, 176, 154–170.
91. Grau, I.; Ardanuy, C.; Calatayud, L.; Schulze, M.H.; Liñares, J.; Pallares, R. Smoking and alcohol abuse are the most preventable risk factors for invasive pneumonia and other pneumococcal infections. *Int. J. Infect. Dis.* 2014, 25, 59–64. [CrossRef]
92. Smith, A.M.; McCullers, J.A. Secondary bacterial infections in influenza virus infection pathogenesis. *Influenza Pathog. Control-Vol.* 2014, 385, 327–356.
93. Lai, C.-C.; Wang, C.-Y.; Hsueh, P.-R. Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? *J. Microbiol. Immunol. Infect.* 2020, 53, 505–512. [CrossRef]
94. Bergoechea, J.A.; Bamford, C.G. SARS-CoV-2, bacterial co-infections, and AMR: The deadly trio in COVID-19? *EMBO Mol. Med.* 2020, 12, e12560. [CrossRef] [PubMed]
95. Guo, L.; Wei, D.; Zhang, X.; Wu, Y.; Li, Q.; Zhou, M.; Qu, J. Clinical Features Predicting Mortality Risk in Patients With Viral Pneumonia: The MubLASA Score. *Front. Microbiol.* 2019, 10, 2725. [CrossRef] [PubMed]
96. Cox, M.J.; Loman, N.; Bogaert, D.; O’Grady, J. Co-infections: Potentially lethal and unexplored in COVID-19. *Lancet Microbe* 2020, 1, e11. [CrossRef]
97. Lansbury, L.; Lim, B.; Baskaran, V.; Lim, W.S. Co-infections in people with COVID-19: A systematic review and meta-analysis. *J. Infect.* 2020, 81, 266–275. [CrossRef] [PubMed]
98. Lagarinha, A.; de Araújo, C.G.S.; Dey, R.S.; Blom, A.W.; Laukkanen, J.A. Physical activity and risk of venous thromboembolism: Systematic review and meta-analysis of prospective cohort studies. *Eur. J. Epidemiol.* 2020, 35, 431–442. [CrossRef]
99. Garcia-Vidal, C.; Sanjuan, G.; Moreno-García, J.; Vázquez, E.; Dey, R.; Blom, A.W.; Laukkanen, J.A. Physical activity and risk of venous thromboembolism: Systematic review and meta-analysis of prospective cohort studies. *Eur. J. Epidemiol.* 2020, 35, 431–442. [CrossRef]
100. Control CFD. Prevention. Influenza and pneumococcal vaccination coverage among persons aged ≥ or = 65 years and persons aged 18–64 years with diabetes or asthma—United States, 2003. *MMWR Morb. Mortal. Wkly. Rep.* 2004, 53, 1007–1012.
101. Defrance, T.; Taillardet, M.; Genestier, L. T cell-independent B cell memory. *Clin. Vaccine Immunol.* 2011, 28, 330–336. [CrossRef] [PubMed]
102. Bonten, M.J.; Huijts, S.M.; Bolkenbaas, M.; Webber, C.; Patterson, S.; Gault, S.; van Werkhoven, C.H.; van Deursen, A.M.; Sanders, E.A.; Verheij, T.J. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. *N. Engl. J. Med.* 2015, 372, 1114–1125. [CrossRef]
103. Semenov, Y.R.; Starmer, H.M.; Gourin, C.G. The effect of pneumonia on short-term outcomes and cost of care after head and neck cancer surgery. *Laryngoscope* 2012, 122, 1994–2004. [CrossRef]
104. Papadatou, I.; Spoulou, V. Pneumococcal vaccination in high-risk individuals: Are we doing it right?
105. Avci, F.Y.; Kasper, D.L. How bacterial carbohydrates influence the adaptive immune system. *Annu. Rev. Immunol.* 2009, 28, 107–130. [CrossRef] [PubMed]
106. Bonten, M.J.; Huijts, S.M.; Bolkenbaas, M.; Webber, C.; Patterson, S.; Gault, S.; van Werkhoven, C.H.; van Deursen, A.M.; Sanders, E.A.; Verheij, T.J. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. *N. Engl. J. Med.* 2015, 372, 1114–1125. [CrossRef]
107. CDC. Vaccines and Preventable Disease. Available online: https://www.cdc.gov/vaccines/vpd/pneumo/index.html (accessed on 21 November 2021).

108. The National Institute for Communicable Diseases. Pneumococcal Conjugate Vaccine Use in the Light of the COVID-19 Pandemic. Available online: https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/advice-for-the-public/pneumococcal-conjugate-vaccine-use-in-the-light-of-the-covid-19-pandemic/ (accessed on 30 April 2021).

109. Harvard Medical School. Preventing the Spread of the Coronavirus. Available online: https://www.health.harvard.edu/diseases-and-conditions/preventing-the-spread-of-the-coronavirus (accessed on 23 November 2021).

110. World Health Organization. Coronavirus Disease (COVID-19) Advice for the Public: Mythbusters. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters?gclid=Cj0KCQw8fAGbCHARlsAGIRRYorv3VeRflgb7f5za4EEeus4hEII_CQX-UuZV4mH1y8SN-cXiVnMaAkcpEAlw_wcB#vaccines (accessed on 5 May 2021).

111. Pawlowski, C.; Puranik, A.; Bandi, H.; Venkatakrishnan, A.J.; Agarwal, V.; Kennedy, R.; O’Horo, J.C.; Gores, G.J.; Williams, A.W.; Halamka, J.; et al. Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations. Sci. Rep. 2021, 11, 4741. [CrossRef] [PubMed]

112. Root-Bernstein, R. Until a Coronavirus Vaccine is Ready, Pneumonia Vaccines may Reduce Deaths from COVID-19. Available online: https://www.discovermagazine.com/health/until-a-coronavirus-vaccine-is-ready-pneumonia-vaccines-may-reduce-deaths (accessed on 15 October 2021).

113. Lewnard, J.A.; Bruxvoort, K.J.; Fischer, H.; Hong, V.X.; Grant, L.R.; Jódar, L.; Gessner, B.D.; Tartof, S.Y. Prevention of COVID-19 among older adults receiving pneumonia conjugate vaccines suggests interactions between Streptococcus pneumoniae and SARS-CoV-2 in the respiratory tract. J. Infect. Dis. 2021, 3, jlab128. [CrossRef]

114. Madhi, S.A.; Klugman, K.P.; Group, T.V.T. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat. Med. 2004, 10, 811–813. [CrossRef]

115. Huijts, S.; Coenjaerts, F.; Bolkenbaas, M.; van Werkhoven, C.; Grobbe, D.; Bonten, M.; Team, C.S. The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPITA trial. Clin. Microbiol. Infect. 2018, 24, 764–770. [CrossRef] [PubMed]

116. Nunes, M.C.; Cutland, C.L.; Klugman, K.P.; Madhi, S.A. Pneumococcal Conjugate Vaccine Protection against Coronavirus-Associated Pneumonia Hospitalization in Children Living with and without HIV. mBio 2021, 12, e02347-20. [CrossRef] [PubMed]

117. Palmu, A.A.; Jokinen, J.; Borys, D.; Nieminen, H.; Ruokokoski, E.; Siira, L.; Puumalainen, T.; Lommel, P.; Hezarel, M.; Moreira, M. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: A cluster randomised trial. Lancet 2013, 381, 214–222. [CrossRef]

118. Root-Bernstein, R. Pneumococcal and Influenza Vaccination Rates and Pneumococcal Invasive Disease Rates Set Geographical and Ethnic Population Susceptibility to Serious COVID-19 Cases and Deaths. Vaccines 2021, 9, 474. [CrossRef] [PubMed]

119. Thindwa, D.; Quesada, M.G.; Liu, Y.; Bennett, J.; Cohen, C.; Knoll, M.D.; von Gottberg, A.; Hayford, K.; Flasche, S. Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality. Vaccine 2020, 38, 5398. [CrossRef] [PubMed]

120. Matanock, A.; Lee, G.; Gierke, R.; Kobayashi, M.; Leidner, A.; Pilishvili, T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥ 65 years: Updated recommendations of the Advisory Committee on Immunization Practices. Morb. Mortal. Wkly. Rep. 2019, 68, 1069. [CrossRef] [PubMed]

121. Bonnave, C.; Mertens, D.; Peetermans, W.; Cobbaert, K.; Ghesquiere, B.; Deschodt, M.; Flammign, J. Adult vaccination for pneumococcal disease: A comparison of the national guidelines in Europe. Eur. J. Clin. Microbiol. Infect. Dis. 2019, 38, 785–791. [CrossRef] [PubMed]

122. Al-Ani, A.H.; Prentice, R.E.; Rentsch, C.A.; Johnson, D.; Ardalan, Z.; Heerasing, N.; Garg, M.; Campbell, S.; Sasadeusz, J.; Macrae, F.A. prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment. Pharmacol. Ther. 2020, 52, 54–72. [CrossRef] [PubMed]

123. Zanettini, C.; Omar, M.; Dinalankara, W.; Imada, E.L.; Colantuoni, E.; Parmigiani, G.; Marchionni, L. Influenza Vaccination and COVID-19 Mortality in the USA: An Ecological Study. Vaccines 2021, 9, 427. [CrossRef]

124. Fink, G.; Orlova-Fink, N.; Schindler, T.; Grisi, S.; Ferrer, A.P.; Daubenberger, C.; Brentani, A. Inactivated trivalent influenza vaccination is associated with lower mortality among COVID-19 in Brazil. BMJ Evid. Based Med. 2021, 26, 192–199. [CrossRef]

125. Marín-Hernández, D.; Schwartz, R.E.; Nixon, D.F. Epidemiological evidence for association between higher influenza vaccine uptake in the elderly and lower COVID-19 deaths in Italy. J. Med. Virol. 2021, 93, 64–65. [CrossRef]

126. Elston, J.W.; Cartwright, C.; Ndumbi, P.; Wright, J. The health impact of the 2014–15 Ebola outbreak. Public Health 2017, 143, 60–70. [CrossRef] [PubMed]

127. World Health Organization. Guidance on Routine Immunization Services during COVID-19 Pandemic in the WHO European Region; World Health Organization: Geneva, Switzerland; Regional Office for Europe: Copenhagen, Denmark, 2020.

128. Grech, V.; Borg, M. Influenza vaccination in the COVID-19 era. Early Hum. Dev. 2020, 148, 105116. [CrossRef] [PubMed]

129. Gostin, L.O.; Salmon, D.A. The dual epidemics of COVID-19 and influenza: Vaccine acceptance, coverage, and mandates. JAMA 2020, 324, 335–336. [CrossRef] [PubMed]
130. Portolés-Pérez, J.; Marques-Vidas, M.; Picazo, J.J.; González-Romo, F.; García-Rojas, A.; Pérez-Trallero, E.; Gil-Gregorio, P.; de la Cámara, R.; Morató, M.L.; Rodríguez, A.; et al. Recommendations for vaccination against pneumococcus in kidney patients in Spain. Nefrologia 2014, 34, 545–551. [CrossRef] [PubMed]

131. COSMO Healthcare. Immunization: Pneumococcal Polysaccharide Vaccine. Available online: https://www.health.gov.on.ca/en/public/publications/immune/pnem.aspx (accessed on 28 October 2021).

132. EACS & BHIVA. Statement on Risk of COVID-19 for People Living with HIV (EACS & BHIVA); EACS: Brussels, Belgium, 2020.